- Home
- NXTC vs CLPR Comparison
NXTC vs CLPR Comparison
Compare NXTC & CLPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXTC | CLPR |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.6M | 51.8M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | NXTC | CLPR |
|---|---|---|
| Price | $13.52 | $3.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | 27.3K | ★ 59.0K |
| Earning Date | 06-08-2026 | 06-05-2026 |
| Dividend Yield | N/A | ★ 11.84% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $22,378,000.00 | ★ $109,997,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.82 |
| 52 Week Low | $0.23 | $3.04 |
| 52 Week High | $15.74 | $4.61 |
Technical Indicators
Market Signals| Indicator | NXTC | CLPR |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 33.07 |
| Support Level | $10.73 | $3.04 |
| Resistance Level | $13.47 | $3.96 |
| Average True Range (ATR) | 1.10 | 0.12 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 64.68 | 6.67 |
Price Performance
Historical ComparisonAbout NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.
About CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.